Bayer opens US ‘science hub’
pharmafile | May 18, 2010 | News story | Research and Development | Bayer, US, acdemia, clinical research
Bayer Schering Pharma has expanded its global research network, opening a new Innovation Center in San Francisco.
The US centre will act as a ‘science hub’ for the company, focusing on developing partnerships with academic research institutions and small life science firm as part of moves to strengthen its pharma product pipeline.
The centre, located in San Francisco’s Mission Bay, will focus on research in cardiology, oncology, women’s healthcare and diagnostic imaging.
It will also house Bayer scientists working on haematology research programmes focused on coagulation factors and the discovery of novel biologic drug candidates.
Professor Andreas Busch, head of global drug discovery for Bayer, said: “Through our newest innovation centre, US academic research institutions and young biopharmaceutical firms will work closely with Bayer scientists and leverage our experience in bringing novel discoveries to market. Working together, we have the potential to create significant benefits for patients.
San Francisco Mayor Gavin Newsom, said: “I’m proud of the City’s work to bring Bayer’s innovative, entrepreneurial spirit to San Francisco.
“We expect the US Innovation Center to further catalyse and anchor the significant activity and growth we’ve already seen at Mission Bay, cementing its place as the premier biotech cluster in the nation.”
Mission Bay is an attractive location for Bayer’s new centre given the growth of the local biomedical research community and state-of-the-art labs the company has leased for the project.
Professor Busch added: “Mission Bay is a hotbed of innovation in the US and key to our decision to co-locate our researchers in this life sciences community. We expect this new focus on US research collaboration to enhance Bayer’s pipeline which features a successful combination of internal excellence with highly partnered approaches in research and development and commercialisation.”
The San Francisco development joins similar innovation centres the Bayer Group has set up to focus research within certain parts of its business, such as the Bayer MaterialScience centre in Dubai and the Bayer CropScience center in Belgium.
Ben Adams
Related Content
Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …
Sharp invests $100m in US and EU manufacturing and packaging facilities
Sharp Services, a pharmaceutical packaging and sterile manufacturing specialist, has announced investments totalling $100m across …
Moderna doses first US patient in phase 1 trial of mRNA-4106 for solid tumours
The START Center for Cancer Research has dosed the first US participant in Moderna’s phase …
